+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-07-01Number of Pages: 208

Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019

Diabetes is a group of metabolic disorders in which pancreas is not able to produce enough insulin (sugar metabolizing hormone) (type-1) or the body develops a resistance to produce insulin and is not able to utilize the produced insulin (type-2). This condition triggers various malignancies and diseases. Diabetes market is a consolidated market and the demand for various advanced devices and medicines is increasing steadily, owing to exponential growth in the prevalence of diabetes across the globe. This report is focused towards identifying the current scenario as well as the future market potential for diabetes drugs and devices globally.

The global diabetes devices and drugs market is segmented into two segments, namely; diabetes devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps and insulin injectors. The second segment of the market, that is, drugs class is fragmented into insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs. Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Oral anti-diabetes drugs are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors, thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes drugs. 

Out of all the above mentioned diagnostic and monitoring devices, continuous glucose monitoring devices segment is expected to grow at a CAGR of 6.6% from 2013 to 2019. Insulin pen is a rapidly growing segment in the global insulin delivery devices market. The rising population of diabetic patients across the globe is the most important driver of the market, followed by extensive R&D practices. According to International Diabetes Federation (IDF), as of 2013, around 382 million people were diagnosed with diabetes, and the number is expected to grow to 592 million by the end of 2035. This rise in diabetic population propels the market growth. Further, due to extensive R&D practices in drugs and devices, large numbers of drugs (around 180) are under pipeline studies. Hence, the market is augmented to grow steadily during the forecast period 2013 – 2019. In addition, rising demand for SGLT2 inhibitors, DPP-IV inhibitors, GLP-1 agonists and long-acting insulin derivatives drive the market of drugs to higher end. In addition to existing drugs, drugs and formulations under pipeline studies (for example, U-300, Afrezza, Dulaglutide and others) are also considered and the forecast for these products is estimated considering their expected approval and commercialization years. 

Geographically, in this report, the diabetes devices and drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). Presently, the North American region is the largest market in the world, owing to the presence of large number of type-1 and type-2 diabetic patients, technological advancements and world-class medical infrastructure. However, Asia-Pacific region is considered as the most promising market during the forecast period 2013 to 2019. High incidence rate of diabetes, steady increase in medical expenditure, increased healthcare awareness towards self-monitoring and management of diabetes are some of the important factors supporting the growth of diabetes devices and drugs market in Asia-Pacific region.

Globally, the market for diabetes devices is dominated by selected number of players, namely; F. Hoffmann La Roche Ltd., LifeScan, Inc. (J&J), Abbott Diabetes Care, and Bayer AG. In addition to this, some other important players that offer an important contribution to the total diabetes devices market include B Braun Melsungen AG and DexCom, Inc. Whereas, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, AstraZeneca plc, Merck, Inc., and Takeda Pharmaceutical Company Limited are the key players having presence in the global diabetes drugs market.

diabetes-devices-and-drugs-market

Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications. This report studies the current as well as future scenario of the diabetes diagnostic devices and drugs market globally. 

The diabetes diagnostic devices and drugs market has been segmented based on devices and drugs available for the treatment the disease. Based on device type, the market is segmented into diabetes diagnostic devices and insulin delivery devices. Diabetes diagnostic devices include analog blood meter, test strips, lancets and lancing devices, continuous glucose monitoring devices and others. The insulin delivery devices segment include insulin syringes, insulin pens, insulin pumps and insulin injectors.

Based on drugs, the market is segmented into insulin derivatives, oral anti-diabetes drugs and non-insulin injectable anti-diabetes drugs. The insulin derivatives segment is further categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. The oral anti-diabetes drugs segment includes various drugs classes such as sulphonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors, GPP-4 inhibitors and SGLT-2 inhibitors. The non-insulin injectable anti-diabetes drugs segment is segmented into GLP-1 analogs and Pramlintide. The market for these devices and drugs has been extensively analyzed based on demand for branded and generic products in each class of drugs and devices. Rising prevalence of diabetic population across various regions of the world, pipeline products from each class, rising preference of patients and healthcare professionals toward technologically advanced monitoring and insulin delivery devices is driving the growth of the diabetes diagnostic devices and drugs market. 

The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2013 to 2019, considering 2012 as the base year. The diabetes devices and drugs market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. 

Geographically, the diabetes diagnostic devices and drugs market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019, along with the CAGR (%) for the forecast period 2013 to 2019. The diabetes diagnostic devices and drugs market study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises a qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis and market attractiveness analysis. In addition, thorough analyses of various events, which occurred in the past five years and are expected to occur during forecast period, are also provided in the market overview section of the report. In this section, the major events, which affected the market and are expected to affect the market are studied. Further, value chain analysis (VCA) for drugs and devices is also provided, which highlights the major stages of the development of drugs and devices. The entire section of market overview plays an important role in understanding the market on a global level.

The diabetes devices and drugs market report also provides a highlight of the competitive landscape of the market wherein the market share analysis of the leading players in the diabetes devices and drugs market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the diabetes devices and drugs market such as Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Company Limited. Market players are profiled based on attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments.

The global diabetes devices and drugs market is segmented into the following categories:
  • Global Diabetes Devices Market, by Devices
    • Diabetes Monitoring and diagnostic devices
      • Analog glucose meter
      • Glucose Test strips
      • Lancets and Lancing devices
      • Continuous glucose monitoring devices
      • Others
    • Insulin Delivery Devices
      • Insulin Syringes
      • Insulin Pens
      • Insulin Pumps
      • Insulin Injectors
  • Global Diabetes Drugs Market, by Therapy
    • Insulin
      • Short-acting insulin derivatives
      • Intermediate-acting insulin derivatives
      • Long-acting insulin derivatives
      • Rapid-acting insulin derivatives
      • Premixed insulin derivatives
    • Oral anti-diabetes drugs class
      • Sulphonylureas
      • Biguanides
      • Meglitinides
      • Thiazolidinediones
      • Alpha-glucosidase inhibitors
      • DPP-4 inhibitors
      • SGLT-2 inhibitors
    • Non-insulin injectable anti-diabetes drugs
      • GLP-1 analogs
  • Global Diabetes Drugs Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)


 
 
Back To Top